The approval is supported by data from the phase 3 FINE-ONE clinical trial.
|Articles|June 11, 2020
Participate in the Managed Healthcare Executive Annual Pharmacy Survey
Health executives and professionals are encouraged to take the short survey to provide Managed Healthcare Executive® with the latest data in the pharmacy industry.
Advertisement
Participate in the 2020 Pharmacy Survey. Health executives and professionals are encouraged to take the short survey to provide Managed Healthcare Executive® with the latest data in the pharmacy industry. Results will be shared in the Managed Healthcare Executive® July issue.
Take the survey:
Advertisement
Related to this article
The randomized ALLIANCE A051701 trial closed early when treatment-related toxicity and mortality were increased without improving PFS in patients with newly diagnosed double-hit lymphoma.
Artificial intelligence (AI) transforms a chaotic, reactive process into an adaptive, proactive system that improves workflow and patient safety.
New European Respiratory Society (ERS) update makes sotatercept a strong add-on recommendation, opening a fourth pathway for pharmacists to manage.
Robin Tumlinson, PharmD, BCOP, discusses how rapidly expanding bladder cancer options are creating new questions around treatment sequencing, toxicity management, biomarker testing, and multidisciplinary care.
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Pharmacists are well equipped to manage DOAC therapy by providing initial education, adherence support, and safety monitoring.
A prospective observational study found microplastics more frequently and at higher levels in lung samples from patients with lung malignancies, although the findings do not establish that the particles cause cancer.
Advertisement
Advertisement
Trending on Pharmacy Times
1
How Pharmacists Overcome PCSK9 Inhibitor Access Barriers
2
From Reactive to Proactive: AI's Role in Modern Pharmacy Safety
3
Trial Ended Early When Venetoclax Plus DA-EPOCH-R Did Not Improve Outcomes in Double-Hit Lymphoma
4
Utilizing 340B Margin to Create a Patient Prescription Assistance Program
5